Pharmaceuticals

Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Performance Report: Global Trends 2026–2030

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the hepatitis b virus (hbv) capsid inhibitors market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Hepatitis B Virus (HBV) Capsid Inhibitors Market between 2026 and 2030?

The hepatitis b virus (hbv) capsid inhibitors market has experienced substantial growth in recent years. Projections indicate it will expand from $0.52 billion in 2025 to $0.59 billion in 2026, showing a compound annual growth rate (CAGR) of 13.7%. This historical growth can be attributed to the global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, and growing pharmaceutical pipeline activity.

The hepatitis b virus (HBV) capsid inhibitors market size is projected to experience significant growth in the upcoming years. It is expected to expand to $0.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This anticipated growth can be attributed to factors such as the broader implementation of combination regimens with immunotherapies, increasing investments in curative HBV treatments, a rise in regulatory approvals for novel antiviral compounds, the expansion of global screening programs, and advancements in next-generation capsid inhibitors. Prominent trends throughout the forecast period include an intensified focus on functional cure strategies for HBV, the accelerated development of capsid assembly modulators, an increase in combination therapy approaches, the expansion of late-stage clinical pipelines, and more effective targeting of viral replication pathways.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

Which Drivers Are Expected To Impact The Hepatitis B Virus (HBV) Capsid Inhibitors Market During The Forecast Period?

The escalating occurrence of hepatitis B virus infections is projected to drive the expansion of the hepatitis B virus (HBV) capsid inhibitors market moving forward. Hepatitis B Virus (HBV) infections are defined as liver infections caused by the hepatitis B virus, which can lead to both acute and chronic conditions. These infections spread through exposure to infected blood or bodily fluids and can result in grave complications such as liver cirrhosis or liver cancer. The primary cause for the rising prevalence of Hepatitis B Virus (HBV) infections is inadequate vaccination coverage, leaving substantial segments of the population unprotected and enabling easier transmission of the virus via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors address hepatitis B virus (HBV) infections by interfering with the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the propagation of infection within the body. For example, in April 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that as of the end of 2022, only 13% of individuals living with chronic hepatitis B had been diagnosed, and roughly 3% (7 million) had received antiviral treatment. For hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures that remain considerably below the global goal of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is stimulating the growth of the hepatitis B virus (HBV) capsid inhibitors market.

How Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Divided Into Segments?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

Which Trends Are Influencing The Performance And Direction Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Leading companies in the hepatitis B virus (HBV) capsid inhibitors market are concentrating on advancing innovations such as oral small molecule capsid assembly modulators, intending to boost antiviral effectiveness, improve patient adherence, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are characterized as antiviral agents administered orally that disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby preventing its replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to commence a clinical trial evaluating novel treatment candidates for chronic hepatitis B (CHB). This initiative aims to utilize Aligos’s advanced capsid assembly modulator technology to enhance antiviral efficacy and expedite the development of next-generation HBV therapies. This launch signifies a key development in Aligos’s commitment to creating effective and potentially curative treatments for chronic hepatitis B patients.

Which Leading Companies Dominate The Hepatitis B Virus (HBV) Capsid Inhibitors Market Share?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

How Does The Hepatitis B Virus (HBV) Capsid Inhibitors Market Perform Across Major Global Regions?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hepatitis B Virus (HBV) Capsid Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30294&type=smp

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795